Antiviral activity of telaprevir (VX‐950) and peginterferon alfa‐2a in patients with hepatitis C
Nicole Forestier, Hendrik W. Reesink, Christine J. Weegink, Lindsay McNair, Tara L. Kieffer, Hui‐May Chu, Susan Purdy, Peter L.M. Jansen, Stefan Zeuzem – 24 August 2007 – Telaprevir (VX‐950), an inhibitor of the hepatitis C virus (HCV) NS3/4A protease, substantially decreased plasma HCV RNA levels in a prior clinical study. The present study evaluated viral kinetics and safety during dosing with telaprevir alone and in combination with peginterferon alfa‐2a for 14 days.